Trial Profile
An Open-Label, Phase II Multicenter Study of Rituximab or Tocilizumab for Steroid-Dependent Immune-Related Adverse Events Due to Immune Checkpoint Blockade
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 10 Apr 2024
Price :
$35
*
At a glance
- Drugs Rituximab (Primary) ; Tocilizumab (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- 05 Apr 2024 Planned End Date changed from 1 Feb 2024 to 1 May 2025.
- 05 Apr 2024 Planned primary completion date changed from 1 May 2023 to 1 May 2024.
- 07 Apr 2022 Status changed from not yet recruiting to recruiting.